{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:10:24Z","timestamp":1662336624500},"reference-count":44,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2018.6906","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T08:41:30Z","timestamp":1540975290000},"source":"Crossref","is-referenced-by-count":0,"title":["A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism"],"prefix":"10.3892","author":[{"given":"Huizhen","family":"Ye","sequence":"first","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyi","family":"Ye","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aizhen","family":"Hou","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Liang","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhong","family":"Kong","sequence":"additional","affiliation":[{"name":"Nephrology Department, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"key20200713115707_b1-etm-0-0-6906","unstructured":"National Center for Chronic Disease Prevention and Health PromotionCS250738-A: National Chronic Kidney Disease Fact Sheet2014https:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/kidney_factsheet.pdf"},{"key":"key20200713115707_b2-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: A cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"key20200713115707_b3-etm-0-0-6906","first-page":"657","article-title":"High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in argentina","volume":"33","author":"Douthat","year":"2013","journal-title":"Nefroloqia"},{"key":"key20200713115707_b4-etm-0-0-6906","first-page":"102","article-title":"Are we overconcerned about secondary hyperparathyroidism and underestimating the more common secondary hypoparathyroidism in our dialysis patients?","volume":"60","author":"Jeloka","year":"2012","journal-title":"J Assoc Physicians India"},{"key":"key20200713115707_b5-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"key20200713115707_b6-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"key20200713115707_b7-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1586\/14737167.2015.1047348","article-title":"The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: A focus on evidence regarding paricalcitol and cinacalcet","volume":"15","author":"Lorenzoni","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key20200713115707_b8-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"key20200713115707_b9-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"e48070","DOI":"10.1371\/journal.pone.0048070","article-title":"Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: A meta-analysis","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"key20200713115707_b10-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20200713115707_b11-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","article-title":"Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713115707_b12-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key20200713115707_b13-etm-0-0-6906","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"key20200713115707_b14-etm-0-0-6906","first-page":"2145","article-title":"Serum detection of thymidine kinase 1 as a means of early detection of lung cancer","volume":"34","author":"Alegre","year":"2014","journal-title":"Anticancer Res"},{"key":"key20200713115707_b15-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"key20200713115707_b16-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key20200713115707_b17-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: A decision support system for evidence-based medicine","volume":"55","author":"Valkenhoef","year":"2013","journal-title":"Decision Support Systems"},{"key":"key20200713115707_b18-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"key20200713115707_b19-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/2046-4053-1-41","article-title":"Sample size and power considerations in network meta-analysis","volume":"1","author":"Thorlund","year":"2012","journal-title":"Syst Rev"},{"key":"key20200713115707_b20-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"New Engl J Med"},{"key":"key20200713115707_b21-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","article-title":"Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients","volume":"15","author":"El-Shafey","year":"2011","journal-title":"Ther Apher Dial"},{"key":"key20200713115707_b22-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713115707_b23-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/ki.2011.226","article-title":"No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: A randomized crossover trial","volume":"80","author":"Hansen","year":"2011","journal-title":"Kidney Int"},{"key":"key20200713115707_b24-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713115707_b25-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"key20200713115707_b26-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key20200713115707_b27-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1523-1755.2005.00517.x","article-title":"First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl","volume":"68","author":"Martin","year":"2005","journal-title":"Kidney Int"},{"key":"key20200713115707_b28-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20200713115707_b29-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key20200713115707_b30-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis","volume":"28","author":"Ross","year":"2008","journal-title":"Am J Nephrol"},{"key":"key20200713115707_b31-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"key20200713115707_b32-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5414\/CNP68010","article-title":"Cinacalcet HCI (Sensipar\/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism","volume":"68","author":"Sterrett","year":"2007","journal-title":"Clin Nephrol"},{"key":"key20200713115707_b33-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A randomized trial of cinacalcet versus Vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20200713115707_b34-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/hdi.12410","article-title":"Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis","volume":"20","author":"Mei","year":"2016","journal-title":"Hemodial Int"},{"key":"key20200713115707_b35-etm-0-0-6906","first-page":"1451","article-title":"Clinical observation of calcitriol combined with cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"30","author":"Han","year":"2015","journal-title":"Drug Clinic"},{"key":"key20200713115707_b36-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11255-015-1195-6","article-title":"Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Cai","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"key20200713115707_b37-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12020-012-9711-2","article-title":"The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: A meta-analysis","volume":"43","author":"Li","year":"2013","journal-title":"Endocrine"},{"key":"key20200713115707_b38-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"key20200713115707_b39-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"key20200713115707_b40-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","article-title":"Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism","volume":"67","author":"Colloton","year":"2005","journal-title":"Kidney Int"},{"key":"key20200713115707_b41-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/1744-9987.12292","article-title":"Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism","volume":"19","author":"Yamada","year":"2015","journal-title":"Ther Apher Dial"},{"key":"key20200713115707_b42-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1053\/ajkd.1998.v32.pm9808142","article-title":"Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats","volume":"32","author":"Slatopolsky","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"key20200713115707_b43-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"c151","DOI":"10.1159\/000319781","article-title":"Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"117","author":"Schumock","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"key20200713115707_b44-etm-0-0-6906","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.mam.2008.04.002","article-title":"Protective and toxic effects of vitamin D on vascular calcification: Clinical implications","volume":"29","author":"Zittermann","year":"2008","journal-title":"Mol Aspects Med"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T23:36:54Z","timestamp":1662334614000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2018.6906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":44,"URL":"https:\/\/doi.org\/10.3892\/etm.2018.6906","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}